A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with Standard of Care in first- and second-line therapy of Stage IIIb or IV NSCLC – The HALO study (HSP90 inhibition And Lung cancer Outcomes)

Van Ingen H (1), Purcea D (1), Brienza S (1), Paz-Ares L (2)

Poster presented at 3rd European Lung Cancer Conference (elcc) in Geneva, Switzerland

Debiopharm SA, Lausanne, Switzerland
Hospital Universitario Virgen del Rocio, Seville, Spain